These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 20371219)

  • 1. Measurement of carboxypeptidase U (active thrombin-activatable fibrinolysis inhibitor) in plasma: Challenges overcome by a novel selective assay.
    Heylen E; Van Goethem S; Augustyns K; Hendriks D
    Anal Biochem; 2010 Aug; 403(1-2):114-6. PubMed ID: 20371219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a sensitive and selective assay for the determination of procarboxypeptidase U (thrombin-activatable fibrinolysis inhibitor) in plasma.
    Heylen E; Van Goethem S; Willemse J; Olsson T; Augustyns K; Hendriks D
    Anal Biochem; 2010 Jan; 396(1):152-4. PubMed ID: 19732738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative substrate specificity study of carboxypeptidase U (TAFIa) and carboxypeptidase N: development of highly selective CPU substrates as useful tools for assay development.
    Willemse JL; Polla M; Olsson T; Hendriks DF
    Clin Chim Acta; 2008 Jan; 387(1-2):158-60. PubMed ID: 17949701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carboxypeptidase U (TAFIa) decreases the efficacy of thrombolytic therapy in ischemic stroke patients.
    Brouns R; Heylen E; Sheorajpanday R; Willemse JL; Kunnen J; De Surgeloose D; Hendriks DF; De Deyn PP
    Clin Neurol Neurosurg; 2009 Feb; 111(2):165-70. PubMed ID: 18980797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limited mutagenesis increases the stability of human carboxypeptidase U (TAFIa) and demonstrates the importance of CPU stability over proCPU concentration in down-regulating fibrinolysis.
    Knecht W; Willemse J; Stenhamre H; Andersson M; Berntsson P; Furebring C; Harrysson A; Hager AC; Wissing BM; Hendriks D; Cronet P
    FEBS J; 2006 Feb; 273(4):778-92. PubMed ID: 16441664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local proCPU (TAFI) activation during thrombolytic treatment in a dog model of coronary artery thrombosis can be inhibited with a direct, small molecule thrombin inhibitor (melagatran).
    Mattsson C; Björkman JA; Abrahamsson T; Nerme V; Schatteman K; Leurs J; Scharpé S; Hendriks D
    Thromb Haemost; 2002 Apr; 87(4):557-62. PubMed ID: 12008935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease.
    Silveira A; Schatteman K; Goossens F; Moor E; Scharpé S; Strömqvist M; Hendriks D; Hamsten A
    Thromb Haemost; 2000 Sep; 84(3):364-8. PubMed ID: 11019956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An assay for measuring functional activated thrombin-activatable fibrinolysis inhibitor in plasma.
    Kim PY; Foley J; Hsu G; Kim PY; Nesheim ME
    Anal Biochem; 2008 Jan; 372(1):32-40. PubMed ID: 17967438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of plasma procarboxypeptidase U in different mammalian species points to a conserved pathway of inhibition of fibrinolysis.
    Schatteman KA; Goossens FJ; Scharpé SS; Hendriks DF
    Thromb Haemost; 1999 Dec; 82(6):1718-21. PubMed ID: 10613660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma carboxypeptidase U (CPU, CPB2, TAFIa) generation during in vitro clot lysis and its interplay between coagulation and fibrinolysis.
    Leenaerts D; Aernouts J; Van Der Veken P; Sim Y; Lambeir AM; Hendriks D
    Thromb Haemost; 2017 Jul; 117(8):1498-1508. PubMed ID: 28692110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a fast kinetic method for the determination of carboxypeptidase U (TAFIa) using C-terminal arginine containing peptides as substrate.
    Willemse J; Leurs J; Verkerk R; Hendriks D
    Anal Biochem; 2005 May; 340(1):106-12. PubMed ID: 15802136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A functional assay for measuring activated thrombin-activatable fibrinolysis inhibitor in plasma.
    Neill EK; Stewart RJ; Schneider MM; Nesheim ME
    Anal Biochem; 2004 Jul; 330(2):332-41. PubMed ID: 15203340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of carboxypeptidase U (TAFIa) activity improves rt-PA induced thrombolysis in a dog model of coronary artery thrombosis.
    Björkman JA; Abrahamsson TI; Nerme VK; Mattsson CJ
    Thromb Res; 2005; 116(6):519-24. PubMed ID: 16181987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carboxypeptidase U (TAFIa): a metallocarboxypeptidase with a distinct role in haemostasis and a possible risk factor for thrombotic disease.
    Leurs J; Hendriks D
    Thromb Haemost; 2005 Sep; 94(3):471-87. PubMed ID: 16268459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma levels of carboxypeptidase U (CPU, CPB2 or TAFIa) are elevated in patients with acute myocardial infarction.
    Leenaerts D; Bosmans JM; van der Veken P; Sim Y; Lambeir AM; Hendriks D
    J Thromb Haemost; 2015 Dec; 13(12):2227-32. PubMed ID: 26340515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction.
    Cruden NL; Graham C; Harding SA; Ludlam CA; Fox KA; Newby DE
    Thromb Res; 2006; 118(2):189-97. PubMed ID: 16055173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carboxypeptidase U (CPU, TAFIa, CPB2) in Thromboembolic Disease: What Do We Know Three Decades after Its Discovery?
    Claesen K; Mertens JC; Leenaerts D; Hendriks D
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33477318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of fibrinolysis by EF6265 [(S)-7-amino-2-[[[(R)-2-methyl-1-(3-phenylpropanoylamino)propyl]hydroxyphosphinoyl] methyl]heptanoic acid], a specific inhibitor of plasma carboxypeptidase B.
    Suzuki K; Muto Y; Fushihara K; Kanemoto K; Iida H; Sato E; Kikuchi C; Matsushima T; Kato E; Nomoto M; Yoshioka S; Ishii H
    J Pharmacol Exp Ther; 2004 May; 309(2):607-15. PubMed ID: 14762098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the procarboxypeptidase U (proCPU, TAFI, proCPB2) system due to hemolysis.
    Mertens JC; Claesen K; Leenaerts D; Sim Y; Lambeir AM; Hendriks D
    J Thromb Haemost; 2019 Jun; 17(6):878-884. PubMed ID: 30887647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The intrinsic enzymatic activity of plasma procarboxypeptidase U (TAFI) can interfere with plasma carboxypeptidase N assays.
    Willemse JL; Polla M; Hendriks DF
    Anal Biochem; 2006 Sep; 356(1):157-9. PubMed ID: 16797476
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.